Maxcyte (MXCT) Restructuring Costs (2025)
Maxcyte (MXCT) posted quarterly Restructuring Costs of $3.1 million for Q3 2025.
Maxcyte (MXCT) Restructuring Costs (2025) Analysis & Trends
Maxcyte (MXCT) has reported Restructuring Costs for 1 consecutive years, with $3.1 million the latest figure, recorded in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 200.08 Bn | 194.48 Bn | 7.27 Bn |
| 2 | Stryker | 129.56 Bn | 126.09 Bn | 4.50 Bn |
| 3 | Medtronic | 119.95 Bn | 110.73 Bn | 6.41 Bn |
| 4 | Boston Scientific | 73.85 Bn | 73.31 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 52.69 Bn | 48.44 Bn | 1.35 Bn |
| 6 | Dexcom | 34.55 Bn | 32.60 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 34.11 Bn | 32.00 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.44 Bn | 23.12 Bn | 4.55 Bn |
| 9 | Steris | 23.22 Bn | 22.73 Bn | 684.20 Mn |
| 10 | Maxcyte | 146.88 Mn | 146.88 Mn | 5.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 3.06 Mn |